Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

LANTHEUS HOLDINGS, INC.

(LNTH)
  Report
Delayed Nasdaq  -  04:00 2022-09-27 pm EDT
67.39 USD   +1.19%
09/13Lantheus, GE Healthcare Say Study Shows 18F flurpiridaz PET Radiotracer Can Improve Coronary Artery Disease Detection
MT
09/13GE Healthcare and Lantheus Phase III Clinical Trial Finds [18F]flurpiridaz PET Radiotracer Could Improve Detection of Coronary Artery Disease
GL
09/13GE Healthcare and Lantheus Phase III Clinical Trial Finds flurpiridaz PET Radiotracer Could Improve Detection of Coronary Artery Disease
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Valuation
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Capitalization1 8059021 9564 633--
Enterprise Value (EV)1 9061 0411 9564 6334 6334 633
P/E ratio ---27,3x28,0x36,6x-
Yield ------
Capitalization / Revenue 2,32x2,66x4,60x5,15x4,60x4,26x
EV / Revenue 2,32x2,66x4,60x5,15x4,60x4,26x
EV / EBITDA 9,59x15,3x19,6x12,1x10,6x9,81x
Price to Book 7,18x1,75x----
Nbr of stocks (in thousands) 39 24866 87167 69168 742--
Reference price (USD) 20,513,528,967,467,467,4
Announcement Date 02/25/202002/25/202102/24/2022---
1 USD in Million
Previous periodNext period
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net sales1 3473394258991 0071 087
EBITDA1 84,058,999,7382436472
Operating profit (EBIT)1 72,434,257,8353396434
Operating Margin 20,8%10,1%13,6%39,3%39,3%39,9%
Pre-Tax Profit (EBT)1 28,6-11,5-75,0237216-
Net income1 31,7-13,5-71,3187203303
Net margin 9,12%-3,97%-16,8%20,8%20,2%27,9%
EPS2 ---1,062,411,84-
Dividend per Share ------
Announcement Date 02/25/202002/25/202102/24/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1
Net sales1 130209224228238242
EBITDA1 40,495,891,991,295,1101
Operating profit (EBIT)1 28,292,788,683,888,090,0
Operating Margin 21,8%44,4%39,6%36,7%37,0%37,1%
Pre-Tax Profit (EBT)1 -41,057,962,057,559,6-26,4
Net income1 -40,243,043,149,950,9-43,1
Net margin -31,0%20,6%19,2%21,9%21,4%-17,8%
EPS2 -0,590,610,610,580,60-0,62
Dividend per Share ------
Announcement Date 02/24/202204/29/202208/04/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Balance Sheet Analysis
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net Debt 101139----
Net Cash position ------
Leverage (Debt / EBITDA) 1,20x2,36x----
Free Cash Flow 58,33,92----
ROE (Net Profit / Equities) 50,6%8,21%----
Shareholders' equity1 62,5-164----
ROA (Net Profit / Asset) ------
Assets1 ------
Book Value Per Share 2,867,69----
Cash Flow per Share -0,30----
Capex1 22,112,5-12,615,917,2
Capex / Sales 6,35%3,68%-1,40%1,58%1,58%
Announcement Date 02/25/202002/25/202102/24/2022---
1 USD in Million
Previous periodNext period
Estimates
Key data
Capitalization (USD) 4 632 515 697
Net sales (USD) 425 208 000
Number of employees 612
Sales / Employee (USD) 694 784
Free-Float 97,6%
Free-Float capitalization (USD) 4 519 255 683
Avg. Exchange 20 sessions (USD) 63 866 807
Average Daily Capital Traded 1,38%
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA